ReviewBrain & NeuroRehabilitation2024
Stroke-Related Sarcopenia: Pathophysiology and Diagnostic Tools.
Review in Brain & NeuroRehabilitation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- High-intensity interval training with robot-assisted gait therapy vs. treadmill gait therapy in chronic stroke: a randomized controlled trial.Journal of neuroengineering and rehabilitation · 2025Trial
- Critical Assessment of Optimal Timing to Initiate Post-Stroke Rehabilitation.Archives of internal medicine research · 2026Article
- Association of Smoking and Alcohol Consumption with the Presence of Sarcopenia at Follow-up in Community-Dwelling People Aged 40-74 Years.Annals of geriatric medicine and research · 2026Article
- Dietary protein intake, animal-to-plant protein ratio and risk of sarcopenia in community-dwelling adults: a 9-year follow-up study.Public health nutrition · 2026Article
- Differential Effects of Stroke Stage and Age on Sarcopenia in Stroke Patients: A Cross-Sectional Study.Life (Basel, Switzerland) · 2026Article
- Post-stroke sarcopenia as a neuromuscular disorder: a mini review of neural mechanisms and clinical implications.Frontiers in neurology · 2026Review
- Narrative Review on Post-Stroke Outcomes Through Recognition of Frailty, Sarcopenia, and Palliative Care Needs.Healthcare (Basel, Switzerland) · 2025Review
- Predictive Value of C-Reactive Protein/Albumin Ratio (CAR) for Malnutrition and Sarcopenia in Acute Ischemic Stroke Patients.Journal of clinical medicine · 2025Article
- Article
- Differences in muscle quality, muscle strength, and functional motor performance between people after stroke and age- and sex-matched apparently healthy adults: a cross-sectional study.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is characterized by the progressive loss of muscle mass and strength and can be categorized as either primary or secondary. Patients who have experienced a stroke may develop sarcopenia, which can adversely impact their functional recovery. The pathophysiology of sarcopenia related to stroke involves nutritional deficiency, disuse atrophy, denervation, and metabolic disturbance. Various evaluation tools are available to diagnose this condition, assessing skeletal muscle mass, muscle strength, and physical function. However, due to the limitations of traditional sarcopenia diagnostic criteria in the context of stroke, there is pressing need to establish diagnostic standards that accurately reflect the disabilities experienced by patients with stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.